JP2024540294A - アルツハイマー病を治療するための方法 - Google Patents

アルツハイマー病を治療するための方法 Download PDF

Info

Publication number
JP2024540294A
JP2024540294A JP2024526586A JP2024526586A JP2024540294A JP 2024540294 A JP2024540294 A JP 2024540294A JP 2024526586 A JP2024526586 A JP 2024526586A JP 2024526586 A JP2024526586 A JP 2024526586A JP 2024540294 A JP2024540294 A JP 2024540294A
Authority
JP
Japan
Prior art keywords
human subject
tau
plasma
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540294A5 (cg-RX-API-DMAC10.html
Inventor
ローラ ニセンバウム，
ティアンルー チェン，
ラジ ラジャゴビンダン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2024540294A publication Critical patent/JP2024540294A/ja
Publication of JP2024540294A5 publication Critical patent/JP2024540294A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2024526586A 2021-11-03 2022-11-02 アルツハイマー病を治療するための方法 Pending JP2024540294A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163275442P 2021-11-03 2021-11-03
US63/275,442 2021-11-03
US202163277127P 2021-11-08 2021-11-08
US63/277,127 2021-11-08
US202263309796P 2022-02-14 2022-02-14
US63/309,796 2022-02-14
US202263343029P 2022-05-17 2022-05-17
US63/343,029 2022-05-17
PCT/US2022/048684 WO2023081194A2 (en) 2021-11-03 2022-11-02 Methods for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2024540294A true JP2024540294A (ja) 2024-10-31
JP2024540294A5 JP2024540294A5 (cg-RX-API-DMAC10.html) 2025-11-12

Family

ID=86241855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526586A Pending JP2024540294A (ja) 2021-11-03 2022-11-02 アルツハイマー病を治療するための方法

Country Status (5)

Country Link
US (1) US20240425573A1 (cg-RX-API-DMAC10.html)
EP (1) EP4426349A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024540294A (cg-RX-API-DMAC10.html)
TW (1) TW202325728A (cg-RX-API-DMAC10.html)
WO (1) WO2023081194A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240753A1 (en) * 2024-05-16 2025-11-20 Creative Bio-Peptides, Inc. Peptides and therapies for treating neurological disorders
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160289310A1 (en) * 2007-01-05 2016-10-06 University Of Zurich Method of Providing Disease-Specific Binding Molecules and Targets
WO2021081101A1 (en) * 2019-10-22 2021-04-29 Biogen Ma Inc. Anti-beta-amyloid antibody for treating alzheimer's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133919A1 (en) * 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Use of tau to monitor immunotherapy
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
EP2885010B1 (en) * 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
WO2021016466A1 (en) * 2019-07-24 2021-01-28 Duke University Compositions and methods for the diagnosis and treatment of alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160289310A1 (en) * 2007-01-05 2016-10-06 University Of Zurich Method of Providing Disease-Specific Binding Molecules and Targets
WO2021081101A1 (en) * 2019-10-22 2021-04-29 Biogen Ma Inc. Anti-beta-amyloid antibody for treating alzheimer's disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CUMMINGS JEFFREY ET AL.: "Aducanumab: Appropriate Use Recommendations", THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE, vol. 4(8), JPN6026015632, 20 July 2021 (2021-07-20), pages 398 - 410, ISSN: 0005842320 *
JANELIDZE SHORENA ET AL.: "Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheime", JAMA NEUROLOGY, vol. 78(2), JPN6026015631, 9 November 2020 (2020-11-09), pages 149 - 156, ISSN: 0005842319 *
OSSENKOPPELE RIK ET AL.: "Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-", EMBO MOLECULAR MEDICINE, vol. 13; e14398, JPN6026015630, 13 July 2021 (2021-07-13), pages 1 - 15, ISSN: 0005842318 *
TOLAR MARTIN ET AL.: "Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Valid", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, 6355, JPN6026015629, 14 June 2021 (2021-06-14), pages 1 - 14, ISSN: 0005842317 *

Also Published As

Publication number Publication date
EP4426349A2 (en) 2024-09-11
WO2023081194A3 (en) 2023-10-26
WO2023081194A2 (en) 2023-05-11
US20240425573A1 (en) 2024-12-26
TW202325728A (zh) 2023-07-01
EP4426349A4 (en) 2025-10-29

Similar Documents

Publication Publication Date Title
US20260091109A1 (en) Method for Treating Alzheimer's Disease
US20220281963A1 (en) Methods for treating alzheimer's disease
US20220372123A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
US20250163135A1 (en) Biomarkers for alzheimer's disease treatment
US20240425573A1 (en) Methods for treating alzheimer's disease
JP2024509960A (ja) 抗アミロイドベータ抗体及びその使用
CN120583962A (zh) 抗N3pGluβ淀粉样蛋白抗体、其剂量及其用途
US20240270830A1 (en) Methods for treating alzheimer's disease
CN118829445A (zh) 用于治疗阿尔茨海默病的方法
WO2025064824A1 (en) Methods for treating alzheimer's disease
NZ788486A (en) Methods for treating Alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260717